Articles

Videos

Podcasts

Clinical

Each time a pharmacist immunizes a patient against one of the 27 infections for which a safe and effective vaccine exists, the profession continues to protect communities against diseases that wreaked havoc on generations. 

Recognizing the Important Work of Pharmacists as Immunizers During World Immunization Week

The analyses are shared at the American Association for Cancer Research Annual Meeting 2022 in New Orleans, Louisiana.

Investigators Release Positive Results From Clinical Trials of Cellular Immunotherapies 

V116 is a novel 21-valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease and pneumococcal pneumonia.

FDA Grants Breakthrough Designation to Merck's Investigational Pneumococcal Conjugate Vaccine Candidate

Measles elimination is the absence of endemic measles transmission in a region or other defined geographical area for 12 months or longer.

Current Vaccination for Measles May Not Be Enough for Elimination 

Each vaccine candidate includes 8 mRNAs, which targets both hemagglutinin and neuraminidase at different doses and ratios. 

Moderna Doses First Participants in Early Trial of Seasonal Influenza Vaccine Candidates

The pharmacist's role in the profession has immensely changed since the COVID-19 pandemic, and it will continue to change with new initiatives for the future and the integration of more public health policies. 

Pharmacy Focus Podcast: Move the Needle Monday- Episode 7

If all HHC agencies adopted policies requiring staff influenza vaccinations, the researchers predicted an 11.25% reduction in the rate of hospital transfers due to respiratory infections.

Increased Flu Vaccinations Among Home Health Workers Could Reduce Patient Illness, Hospitalization

Additional support is necessary to ensure that infrastructure development continues and that all pharmacists have the necessary tools to continue to provide immunization services.

Partnership Between Public Health and Pharmacy: Opportunities to Increase Resource Sharing, Efficiency, and Improved Health Outcomes

Moderna’s COVID-19 Vaccine Phase 2/3 Study in Young Children Meets Primary Endpoint

RSVpreF gets breakthrough designation for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in individuals 60 years of age or older.

FDA Awards Breakthrough Therapy Designation to Vaccine Candidate for RSV

® Immunization Resource Center is a comprehensive resource for clinical news and expert insights on common immunizations, such as flu, zoster, and COVID-19 vaccines.